The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously recommended Moderna's mRNA influenza vaccine, mFlusiva, for adults 50 and over. The vaccine provides a potentially stronger protection against the flu and can be produced more reliably and quickly than traditional flu vaccines. The VRBPAC's recommendation is a step towards the potential approval and availability of the vaccine for the next flu season, despite sustained criticism of vaccines from President Trump and Health and Human Services Secretary Robert F. Kennedy Jr.
Original Article Source Link:
https://www.npr.org/2026/06/18/nx-s1-5863570/flu-vaccine-mrna-moderna-fda